Finally, as demonstrated in a cross-sectional study, EUS has greater sensitivity than other diagnostic procedures in identifying pancreatic lesion in patients with a proven MEN-1 mutation or with a MEN-1 manifestation and a mutation carrier in a first-degree family member (detection rate of 94% versus 22% and 12% with CT/MRI or SRS, respectively) [26], suggesting a possible role in the follow-up of patients with MEN-1. This evidence concerns the gene MEN1 and multiple endocrine neoplasia type 1.